2014

Top Five Pharmaceutical Company Joins with Max Neeman on Groundbreaking Diabetes, Hypertension Prevalence Study

RESEARCH TRIANGLE PARK, N.C., Jan. 6 /PRNewswire/ -- One of the top global pharmaceutical companies has initiated an observational study on the prevalence of Diabetes and Hypertension called SITE (Screening India's Twin Epidemics) in collaboration with Max Neeman International, an India based Contract Research Organization specializing in Phase II-IV clinical trials for pharmaceutical, biotechnology, device and nutraceutical companies. The study surveying both the ailments has been initiated for the first time in India. It will focus on the prevalence of the twin epidemic in India (Diabetes & Hypertension). This observational study is currently being conducted in six regions encompassing 12000 patients cumulatively (2000 patients per region). Site management and data analysis for all the regions is being managed by Max Neeman International.

About Max Neeman International

Max Neeman International is one of the leading and largest CROs in India. Our specialty is that we offer services for the successful conduct of Phase II-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2000 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in 22 cities with 5 regional offices. Please contact Donald Swankie, Vice President of Business Development for more information (donald.swankie@neeman-medical.com/ +1.919.424.3345). http://www.neeman-medical.com

SOURCE Max Neeman International



RELATED LINKS
http://www.neeman-medical.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.